Indian Pharmacy Graduates' Association was Established In The Year 1973. The Association is registered as a society under the Societies Registration Act, 1860.
The Association Is Affiliated To Indian Pharmaceutical Congress Association (IPCA), the Federal Body Of The Five Associations Namely IPGA, IPA, IHPA, APTl And AlDCOC. IPGA Has Got The Income Tax Exemption Under Section 80G (5) (VI)) Of The Income Tax Act, 1961.
Indian Pharmacy Graduates Association is national level association of Indian Pharmacy Graduates. It has been working from the last 30 years for the Up liftment of professionals of pharmacy. The association has a mission to improve the professional status of pharmacy graduates and to secure their rightful place in pharmacy and allied professions. At present IPGA has around 6100 Life Members in 21 state branches all across the country.Read More
One Day National Conference Organized by MESCO Institute of Pharmacy, Amroha Sponsored by Indian Pharmacy Graduates’ Association(IPGA) Theme: QSAR Antiviral Agents vs SARS CoV2: An Overview 14th MAY, 2022 09:15-10:00 Registration & KIT Distribution 10:00-11:00 Inauguration Introductive note by Dr. Gazala Parveen (10:00- 10:02 am) Lamp Lightening(10:02-10:04AM) Recitation of Quran by Mohd Nazir B.P-2 Year(10:04AM-10:07AM) Felicitation of Guest by Management, MIP (10:07AM-10:12AM) Welcome Address by Principal MIP, Dr. Mujeeb Ur Rahman (10:12AM-10:14AM) Release of souvenir(10:14AM-10:15AM) Address by, Dr. Arun Garg, Gen. Secretary IPGA (10:15-10:18AM) Address by, Dr. Vijay Bhalla, Treasurer IPGA (10:18-10:21AM) Address by, Dr. Satendra K Rajput, Joint Secretary IPGA Central (10:21-10:23AM) Address by, Dr. G. Jeyabalan, President IPGA Alwar Local Cahpter (10:23-10:26 AM) Address by Chief Guest, Dr. Atul Kumar Nasa, President IPGA (10:26-10:30AM) Presidential Address by MIP Chairman, Mr. Kamal Faruqui(10:30AM-10:33AM) Inauguration & Declaration of IPGA- Amroha Local Chapter by President IPGA Dr. Atul Kumar Nasa (10:33AM-10:35AM) Distribution of certificate IPGA Life Membership (10:35AM-11:00AM) 11:00-11:20 Tea Break Venue: Lawn MIP 11:20-12:05 Scientific Session-I, Venue: MIP Auditorium Topic: QSAR Antiviral Agents vs SARS CoV2 Dr. Murali Dhanashekran, Professor Department of Drug Discovery and Development, Auburn University, USA 12:05-12:50 Scientific Session-II, Venue: MIP Auditorium Topic:Therapeutic importance of Antiviral drugs and Repurposing of some drugs for Covid-19 Prof.(Dr.) Devender Pathak, Dean and Director, Rajiv Academy for Pharmacy, Mathura 12:50-01:35 Scientific Session-III, Venue: MIP Auditorium Topic: Herbal and Traditional drugs: Hope against COVID 19 Dr. Tanveer Naved,Head of Institution,Amity Institute of Pharmacy, Amity University, Noida 01:35-02:05 Lunch Break Venue: Lawn MIP 02:05-02:20 Poster Session 02:20-02:45 Valedictory Function Prize distribution for scientific posters Honor to different colleges for their contribution by Momento Honor to LOC members by Momento 02:45-02:50 Vote of Thanks by Mr. Shabi Ahmad (Vice Chairman, MIP) 02:50-03:00 Tea Break Venue: Lawn MIP
The Ahmedabad-based company, part of the Rs 14,000-crore Torrent Group, is the only domestic pharma co that has invested nearly $1 bn in local acquisition over the last three years. It expects its future growth avenues from India, Brazil and Germany. The company also focuses on the launch of products in the segment of cardiology and diabetes, which is the fastest growing segment in India. Torrent Pharmaceuticals is optimistic that the future of Indian drug makers is in the domestic market, as it looks at new launches in the lucrative chronic therapy areas.
The growth trajectory for the Indian pharmaceutical industry is likely to remain at 10-13 per cent in 2020- 21 despite challenges, according to rating agency ICRA. According to ICRA, The expected growth in the next financial year is on the back of healthy demand from the domestic market given increasing spend on healthcare along with improving access. This along with abatement in pricing pressure for the US market, new launches and market share gains for existing products and consolidation benefits will drive growth in 2020-21, it added.
Glenmark Pharma has sold its gynaecology business to private equity firm True North backed Integrace Pharma in an attempt to cut down debt of the company. The sale of the gynac business comes two years after it sold its orthopedic business to the same company. Integrace will pay Rs 115 crore for four products of the portfolio that includes products like Dubagest, Mumfer and Fenza. These three products currently have sales of Rs 60 crore and are growing by 15%.
Eli Lilly has revealed a new global licensing and research collaboration with Sitryx, in order to study up to four novel preclinical targets identified by. The collaboration is set to grant Lilly an exclusive, worldwide license to develop and commercialise up to four novel immunometabolism targeted therapeutics, including Sitryx's two lead projects, leading to a a five-year research collaboration to support the development of the therapeutics. The companies have confirmed that under the terms of the agreement, Sitryx will receive an upfront payment of $50 million, and Lilly will make a $10 million equity investment in Sitryx. Also, the latter will be eligible to receive potential development milestones up to $820 million, as well as commercialisation milestones and royalty payments on potential sales in the mid- to high-single digit range.
Unichem is recalling 1.91 crore units of Clonidine Hydrochloride tablets from the US market because of failed impurities/degradation specifications. This recall is initiated as a precautionary measure due to potential migration of Benzophenone at very low level into product from container label, the United States Food and Drug Administration(USFDA) said and Macleods is recalling 4,694 bottles of Pioglitazone and Metformin Hydrochloride tablets used for treating high BP because of subpotent drug: out of specification assay result, below specification, for two lots of Pioglitazone And Metformin Hydrochloride tablets, the USFDAsaid.
Dr Reddy's Laboratories on Wednesday announced an agreement with Wockhardt Ltd. to acquire select divisions of its branded generics business in India, Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs 1,850 crore. The agreement comprises a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS, dermatology, gastroenterology, pain and vaccines. Wockhardt will transfer Dr Reddy's related sales and marketing teams; and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees. The business undertaking is being transferred on a slump sale basis, according to the company.
F-2, Shopping Complex, A-Block, Meera Bagh, New Delhi